Mohammad AskarPublic working copy · medical review pending

Coats, MacTel and phakomatoses · 216

Coats disease, macular telangiectasia and phakomatoses: a clinical lecture guide

A complete teaching draft on Coats disease, macular telangiectasia and the ocular phakomatoses. The original lecture structure, tables, numbers, questions and patient sections are kept, and the places where the original wording needs clinical qualification are marked.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Coats disease is a sporadic, mostly unilateral exudative retinal telangiectasia and the critical differential diagnosis of retinoblastoma in a child. Leukocoria always needs urgent assessment. The Shields stages guide treatment but do not prescribe one operation. Macular telangiectasia type 2 is a bilateral neurodegenerative disease: anti-VEGF treats neovascularisation, not the cavities. Ocular signs of a phakomatosis should trigger syndrome-specific, individual surveillance.

Terminology and draft status

Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.

01Why these diseases belong together

This lecture joins two groups of diseases. The first group is retinal vascular disease with leaking vessels, above all Coats disease and macular telangiectasia. The second group is the phakomatoses, which are neurocutaneous syndromes with hamartomas in several organs. Both groups need two skills at once: careful morphological diagnosis at the fundus and a structured systemic assessment. 1

Some of these diseases threaten vision, and some are associated with tumours that can be life-threatening, so the topic is relevant in daily practice and in the specialist examination. Coats disease is the diagnosis that must be separated quickly from retinoblastoma in a child with a white pupil. Macular telangiectasia has moved from a descriptive classification to a therapeutic field, because a cell-based implant was approved in the United States in 2025 for selected adults. The ocular phakomatoses are often the first visible sign of a serious systemic disease, so the eye examination can start a diagnostic pathway that goes well beyond the eye. 1 2

The original lecture names three red flags: leukocoria, progressive visual field loss and a tomato-catsup fundus. They are useful reminders, but none of them is a diagnosis on its own. Leukocoria requires urgent exclusion of retinoblastoma. A progressive field defect requires a careful differential diagnosis that includes neurological disease. The tomato-catsup appearance describes a diffuse choroidal hemangioma and has to be confirmed with imaging. 1

Why these diseases belong together
Topic or diseaseCore concepts (lecture)Guideline recommendationsCritical findings and evidenceExamination-relevant exceptions
Coats disease70 % male, unilateral, exudative, temporal (population figures).Examination under anaesthesia for leukocoria; original S3: MRI before CT; MRI does not exclude calcium.Chromosome 3/13 instability (original, untraced); lipid exudates; no calcification (absence does not exclude retinoblastoma).Associated with FSHD, Turner syndrome and retinitis pigmentosa (Coats-like changes).
MacTel type 2Bilateral, neurodegenerative, older patients.OCT (cavitations); DOG: intravitreal anti-VEGF only for CNV.Ellipsoid zone loss; ENCELTO approved in the United States on 5 March 2025 for adult idiopathic type 2.Temporal accentuation; visual loss often through atrophy; cavities are not oedema.
NF1 versus NF2Lisch nodules (NF1) versus schwannomas (NF2).Clinical optic-pathway surveillance; MRI when indicated, not automatic routine screeningChromosome 17 (NF1) versus chromosome 22 (NF2).Lisch nodules are visually neutral and increase with age (not 100 % at 21); NF2: posterior subcapsular cataract.
Sturge-Weber syndromeNevus flammeus; glaucoma risk 30–70 %.Primary surgery for congenital glaucoma (individual decision).Tomato-catsup fundus (diffuse choroidal hemangioma).Glaucoma risk persists lifelong.
VHLCapillary hemangiomas; screening priority.Regular screening: kidney, pheochromocytoma, central nervous system.Chromosome 3; prominent feeder vessels at the fundus.The ophthalmic first diagnosis can save lives (original teaching).
Louis-BarRecessive; ataxia plus telangiectasias.Monitor immunodeficiency; AFP is supportive, CA-125 is not an established diagnostic markerConjunctival vessels; chromosome 11 (ATM gene).Only recessive phakomatosis in this selection; radiosensitivity is individual.

02Coats disease: a sporadic exudative telangiectasia

Coats disease is an exudative retinal telangiectasia that is not inherited. The original lecture calls it idiopathic, and that word is still a reasonable description of current understanding: the cause of the sporadic form is not established. The disease is characterised by telangiectatic and aneurysmal retinal vessels, a breakdown of the blood–retina barrier, and lipid-rich xanthochromic exudation with subretinal fluid. 1

The original demographic description is a manifestation mostly before the 8th year of life, a proportion of 70 % male patients, and unilateral disease in 95 % of cases. These are population descriptions taken from the lecture. They were not re-verified against a primary cohort in this review, and they never predict the findings in one child. A unilateral white pupil in a boy is still a retinoblastoma until it has been excluded. 1

The vascular malformations are found preferentially temporal to the macula. Aneurysms and dilated telangiectatic segments leak, and the resulting exudation can raise a retinal detachment. This sequence explains why the clinical picture ranges from a few peripheral vascular changes to a total exudative detachment with secondary glaucoma. 1

The original text adds that research has shown genomic instability on chromosomes 3 and 13 despite the clinical classification as a non-genetic disease. That claim is recorded here as an unresolved original statement. No primary source for it was inspected in this review, and it is neither a diagnostic criterion nor proof of heredity. Leaving it unresolved does not mean that the original observation is wrong; it means that the evidence was not verified. 1

Coats-like vascular changes can occur in other conditions, and the lecture names facioscapulohumeral muscular dystrophy (FSHD), Turner syndrome and retinitis pigmentosa. When such a change appears in a child with additional systemic features, the syndrome should be considered. This association does not turn typical Coats disease into a hereditary disease, and it does not replace the tumour work-up. 1

One primary retrospective clinical series reported150 patients/158 eyes, median age5 years(range1 month–63 years),114male(76%) and142unilateral(95%). Its referral population and broad age range limit generalisation; it does not establish the original male proportion or a strict childhood age boundary for every setting. 1 5

03Shields stages: description, urgency and individual treatment

The Shields classification is a staging of exudation and detachment, not a list of operations. It helps to describe how far the disease has progressed, to compare follow-up examinations, and to decide how quickly treatment is needed. A stage should always be documented together with disease activity, foveal involvement, exudation, intraocular pressure and media clarity. 1

Stage 1 means retinal telangiectasia without exudation. The lecture's consequence is close observation so that the start of progression is recognised. This is reasonable only with a defined follow-up interval and a clear plan for what will trigger treatment; a single examination cannot exclude progression. 1

Stage 2 means telangiectasia with exudation. Stage 2A is extrafoveal and can often be treated with targeted laser photocoagulation or cryotherapy of the leaking vessels. Stage 2B involves the fovea, where exudation threatens central vision, and the lecture combines laser or cryotherapy with intravitreal medication to reduce macular oedema. The choice is individual, and macular exudation is an urgent treatment problem rather than a reason for waiting. 1

Stage 3 means retinal detachment. In stage 3A the detachment is subtotal, and 3B describes a total detachment. A total exudative detachment usually needs more than one measure: subretinal drainage may be required so that the retina can lie flat enough for laser, and the leaking vessels still have to be closed. This is the stage in which the lecture describes a combination of surgery, laser, cryotherapy and intravitreal medication; the exact combination is decided case by case. 1

Stage 4 is a total detachment with secondary glaucoma with an individually assessed pressure mechanism, and stage 5 is the end stage. The original equates stage 5 with phthisis bulbi. That is qualified here: advanced end-stage Coats disease can end in a shrunken, disorganised eye, but stage 5 is not invariably phthisis, and the course depends on activity, previous treatment and complications. The stage describes severe disease; it does not by itself determine that the eye will shrink. 1

04Coats disease versus retinoblastoma: what a sign can and cannot prove

In paediatric ophthalmology Coats disease is the critical differential diagnosis of retinoblastoma. The first clinical rule is therefore not a subtle sign but a process rule: a child with leukocoria needs urgent assessment under anaesthesia, fundus visualisation and imaging, and the tumour must be excluded before the exudative disease is treated as benign. 1

The original refers to the German S3 guideline on retinoblastoma, which it groups under DOG/AWMF, and says that magnetic resonance imaging (MRI) is preferred to computed tomography (CT) in order to avoid radiation. The full current guideline was not inspected for this review. The clinical principle is sound but needs precision: MRI shows soft-tissue extent, optic nerve involvement and extraocular disease, while CT is more sensitive to calcium. MRI cannot exclude calcification, and a normal MRI does not exclude retinoblastoma. 1

The lecture states that retinoblastoma often shows calcification, which is absent in Coats disease. Calcification supports the diagnosis of retinoblastoma, and ultrasound can demonstrate it without radiation. The reverse statement is the dangerous one: the absence of calcification does not exclude retinoblastoma, because calcium is not present in every tumour and dense exudates can mimic tumour findings. 1

The original calls double circulation pathognomonic for retinoblastoma. This is not a validated RB-specific rule: the term describes tumour and retinal vascular circulations and is classically discussed in other intraocular tumours. Neither its presence nor absence establishes or excludes retinoblastoma. Keep the original term pending an exact primary-source clarification and use specialist multimodal assessment. 1

The lecture also contrasts the colour of the pupillary reflex: yellowish and lipid-rich in Coats disease, chalky white to pink-creamy in retinoblastoma. Colour is a soft clue only. A yellow-white reflex can occur in retinoblastoma, and a Coats exudate can look chalky. No colour description can replace examination under anaesthesia and imaging. 1

Two further differences help with orientation but not with certainty. Coats disease is almost always unilateral, while bilateral retinoblastoma suggests a germline mutation; however, unilateral retinoblastoma exists. The lecture's practical message is retained: in any child with a white pupil, the tumour work-up comes first, and the exudative diagnosis is made after it. 1

05Treating Coats disease without turning a technique into a rule

Laser photocoagulation of leaking telangiectatic vessels is the main treatment in moderate stages. The original expert tip is to use a longer exposure time with lower energy in order to achieve a thermal effect without provoking bleeding. That is a reasonable technique preference, not a universal protocol: spot size, duration, power and the number of sessions depend on the location, the media and the response. 1

Intravitreal anti-VEGF agents and steroids are used as adjuncts to reduce exudation and macular oedema. They do not close the abnormal vessels permanently and are not a cure. In children they require close monitoring for cataract and raised intraocular pressure, and anti-VEGF treatment can be followed by traction or fibrosis, so the follow-up must look for both improvement and new complications. 1

The lecture describes a specialised surgical technique attributed to Dr Al-Qadri for massive subretinal fluid: an infusion into the anterior chamber to keep the intraocular pressure stable during surgery, followed by external drainage of the subretinal fluid through a 25G or 27G trocar at the site of maximal fluid, with the aim of reducing proliferative vitreoretinopathy in childhood. This review did not verify the attribution, the technique details or the outcome claim. It is therefore retained as an original, unverified surgical description and not as a universal recipe; surgery in a child's eye carries its own risks and is an individual decision. 1

Follow-up is part of the treatment. Disease activity, exudation, subretinal fluid, the laser scars, intraocular pressure, lens changes and amblyopia all need review. Amblyopia therapy matters even when the retina is stable, because a child can lose vision from disuse while the anatomical result looks acceptable. Long-term follow-up is the rule in extensive disease. 1

06Macular telangiectasia: distinguish vascular and neurodegenerative types

The neurodegenerative model applies mainly to type 2, whereas type 1 is predominantly vascular. Use OCT and selected fluorescein angiography to define the pattern; the available modalities and clinical question determine the sequence. 1

Type 1 is unilateral and aneurysmal, usually temporal to the fovea, and the lecture regards it as a localised variant of Coats disease. Its predominant mechanism is vascular, with aneurysms and exudation, and the treatment named in the lecture is laser or intravitreal medication when oedema is present. It is not the bilateral neurodegenerative picture of type 2. 1

Type 2 is bilateral, idiopathic and neurodegenerative, manifests in the 5th to 7th decade and is the most common form. It is temporally accentuated, and visual loss is often caused by atrophy rather than by oedema. These features are the reason why a macular cavity in type 2 must not automatically be read as fluid that will respond to an injection. 1

Type 3 is bilateral but rare, with an occlusive pattern and capillary loss. It is best regarded as a rare and largely historical classification within the spectrum; it should not be used to describe every atypical vascular presentation of the macula. 1

The type 2 morphology includes hyporeflective cavitations, loss of the ellipsoid zone and foveal atrophy, and crystalline deposits are part of the clinical picture. The cavities and crystals are structural changes, not necessarily exudative oedema. This distinction is the basis of the treatment rule that follows. 1

Anti-VEGF treatment is indicated for a secondary choroidal neovascularisation (CNV) in type 2 disease, not for the neurodegenerative cavities themselves. The lecture cites a statement of the German Ophthalmological Society (DOG) for this rule. A neovascular membrane is a treatable complication; the underlying atrophy is not reversed by an injection, and treating every cavity with anti-VEGF exposes the patient to injections without a biological target. 1

07The cell implant: regulatory facts, trial numbers and limits

The original reports that in March 2025 the NT-501 implant, an encapsulated cell therapy, received approval from the United States Food and Drug Administration (FDA), that it releases ciliary neurotrophic factor (CNTF) continuously, and that it slows atrophy progression significantly. The regulatory detail is corrected here. The approved product is ENCELTO (revakinagene taroretcel-lwey), and the approval on 5 March 2025 is a United States approval for adult patients with idiopathic macular telangiectasia type 2. NT-501 is a development alias, not an established generic name, and Renexus or Densalt are historical names from the original material, not current product names. No German or European approval is claimed. 2 3

The approval rests on two sham-controlled, multicentre randomised trials. The first randomised 120 participants and had 115 in the efficacy analysis, 58 treated and 57 sham. The second randomised 119 and had 113 in the efficacy analysis, 59 treated and 54 sham. Participants had ellipsoid zone loss between 0.16 and 2.0 mm² and visual acuity of at least 54 letters, equivalent to 20/80, and eyes with neovascular macular telangiectasia were excluded. Those entry criteria define the population in which the evidence applies. 2 3

The primary endpoint was the 24-month rate of ellipsoid zone area loss. In the first trial the rate was 0.075 mm² with treatment versus 0.166 mm² with sham, a difference of −0.091 mm² (95 % confidence interval −0.13 to −0.06), p<.0001. In the second trial the rate was 0.111 mm² versus 0.160 mm², a difference of −0.049 mm² (95 % confidence interval −0.089 to −0.008), p.0186. This is a rate of area loss over 24 months, not the absolute change over 24 months, and no annualised unit is added here. 2 3

Microperimetry sensitivity loss differed by −17.75 dB (95 % confidence interval −32.58 to −2.91, p.02; 7 and 4 missing values) in one trial and by −1.95 dB (95 % confidence interval −20.33 to 16.43, p.83; 7 and 6 missing values) in the other. The structural benefit therefore does not establish restoration of vision: the functional results are inconsistent, missing data are present, the participants were selected adults, and there was no head-to-head comparison with anti-VEGF treatment. 2 3

Pooled safety data cover 117 treated and 111 sham participants. Delayed dark adaptation occurred in 27 treated participants (23.1 %) versus 1 sham participant (1 %), and suture-related complications in 18 (15.4 %) versus 3 (2.7 %). The intervention is surgical, needs specialised follow-up, and its benefit is measured mainly on a structural endpoint. No full operative instruction or complete figure appraisal is claimed in this review. 2 3

08Neurofibromatosis and tuberous sclerosis: what the eye can reveal

The phakomatoses are multisystem hamartosis syndromes, and the ophthalmologist often contributes the first diagnosis. The lecture rightly demands interdisciplinary care involving ophthalmology, neurology, dermatology and oncology. The eye finding is an entry point into a surveillance programme; it is not a substitute for genetic and systemic assessment. 1

Neurofibromatosis type 1 (von Recklinghausen disease) is caused by a defect on chromosome 17 in the neurofibromin gene. The ocular signs named in the lecture are Lisch nodules, which are iris hamartomas, and optic pathway glioma with fusiform thickening of the optic nerve. The original states a prevalence of 100 % for Lisch nodules from the 21st year of life. That absolute figure is qualified: Lisch nodule prevalence increases with age, but it is not 100 % at a defined age, and the nodules themselves are visually neutral. 1 4

Neurofibromatosis type 2 is caused by a defect on chromosome 22 in the merlin gene. The lecture calls bilateral vestibular schwannomas pathognomonic and adds posterior subcapsular cataract and retinal hamartomas to the ocular findings. Bilateral vestibular schwannomas are indeed the classical core of the disease, but the word pathognomonic is qualified here. The current nomenclature of NF2-related schwannomatosis is also noted as pending official verification in this review, so the original term NF2 is retained. 1

The original table adds a meningioma of the optic nerve sheath and calls the sign Schienenzustand. That term is retained as an unresolved original expression. An optic nerve sheath meningioma can occur in neurofibromatosis type 2, but a descriptive optic nerve sign is not pathognomonic for it, and imaging interpretation needs a specialist. The term is not corrected here because no authoritative source was inspected for it. 1

Tuberous sclerosis complex (Bourneville-Pringle disease) is caused by a variant in TSC1 on chromosome 9 or TSC2 on chromosome 16. The retinal lesion is an astrocytic hamartoma, and the lecture describes three morphological types: flat and transparent, multinodular and calcified with a mulberry appearance, and mixed forms. All three are retained. The calcified mulberry type is the classic ophthalmoscopic picture, but it is not the only one, and these lesions usually do not reduce vision. 1

The systemic signs named in the lecture are facial angiofibromas, historically called adenoma sebaceum, intellectual disability and epilepsy. The qualification is that tuberous sclerosis is a multisystem diagnosis and does not require a universal triad. Skin, neurological, renal and other manifestations vary between patients, and the retinal hamartoma is often asymptomatic. Finding it should prompt syndrome assessment, not a diagnosis based on the eye alone. 1

09Sturge-Weber, von Hippel-Lindau and ataxia-telangiectasia

Sturge-Weber syndrome combines a facial vascular malformation with ocular and neurological involvement. The skin lesion is a nevus flammeus, or port-wine stain, in the trigeminal distribution, and the lecture emphasises the forehead and upper face. The ocular risk is ipsilateral glaucoma, quoted in the lecture as 30 % to 70 %, plus a diffuse choroidal hemangioma that produces the tomato-catsup fundus. The glaucoma range is context dependent: age, extent of the skin lesion, episcleral venous pressure and angle dysgenesis all influence the risk. 1

The lecture's DOG/BVA guideline summary states that in the congenital form of Sturge-Weber glaucoma, primary surgical intervention with goniotomy or trabeculotomy is the gold standard, with lifelong intraocular pressure monitoring. This is qualified: glaucoma in these eyes is often difficult to control and surgery is frequently needed, but not every patient needs a primary operation, and goniotomy is not possible or appropriate in every angle. The route is individual, and the lifelong monitoring statement is retained. 1

Von Hippel-Lindau disease is caused by a defect on chromosome 3. The ocular hallmark is the retinal capillary hemangioma, described as exophytic and red with prominent feeder and draining vessels; the modern pathological term is retinal hemangioblastoma. The disease also causes renal cell carcinoma, pheochromocytoma and central nervous system lesions, and the lecture calls screening obligatory. That is qualified to lifelong, age- and risk-adjusted surveillance in a specialist programme, because the timing of imaging differs between organs and families. 1

The lecture's screening statement is an annual ophthalmoscopy from early childhood, with lifelong systemic monitoring. That schedule is retained as the original recommendation and not as a verified current protocol. Small retinal hemangiomas are treated with laser photocoagulation using long duration and low energy, and photodynamic therapy (PDT) can be added when exudation persists. Both are individual decisions, and the original claim that the ophthalmic first diagnosis often saves lives remains a teaching statement rather than a measured outcome. 1

Ataxia-telangiectasia is the only autosomal recessive condition in this selected group. It is caused by biallelic variants in the ATM gene on chromosome 11, and the lecture describes cerebellar ataxia, immunodeficiency and conjunctival telangiectasias, with manifestation between the 5th and 8th year of life. The qualification is important: the statement that it is the only recessive phakomatosis refers to this teaching selection and not to all known neurocutaneous syndromes. 1

Laboratory support in the original is a raised alpha-fetoprotein (AFP) and CA-125, with confirmation by Western blot showing absence of the ATM protein. AFP is often raised and is a classic marker, but it is not always raised, particularly in young children. CA-125 is not an established universal diagnostic test for ataxia-telangiectasia. Western blot can support the diagnosis but is not the only confirmatory route, because genetic testing is central. These distinctions prevent a normal test from being read as exclusion. 1

Radiosensitivity in ataxia-telangiectasia is a further point that needs calibration. The original lists it as an examination fact. It is clinically relevant, but the sensitivity varies between patients, so necessary imaging should not be refused absolutely; the responsible approach is to discuss the indication, to use the least burdensome adequate study and to inform the radiology team. None of this replaces the specialist management of the syndrome. 1

What are the main learning points?

Coats disease is a sporadic, mostly unilateral exudative retinal telangiectasia and the critical differential diagnosis of retinoblastoma in a child. Leukocoria always needs urgent assessment. The Shields stages guide treatment but do not prescribe one operation. Macular telangiectasia type 2 is a bilateral neurodegenerative disease: anti-VEGF treats neovascularisation, not the cavities. Ocular signs of a phakomatosis should trigger syndrome-specific, individual surveillance.

When is assessment urgent?

A white or yellow pupil reflection (leukocoria), a new squint, or unexplained visual loss in a child needs urgent assessment to exclude retinoblastoma. Sudden visual loss, severe pain, marked inflammation, a rise in eye pressure, or suspected infection or neurological disease also need prompt care.

References and access status

  1. 1
    Immutable original export; own Coats, macular telangiectasia and phakomatoses lecture; examiner voice and recording unchecked

    Complete export read; original attribution and any recording, transcript or appointment not independently verified.

  2. 2
    FDA ENCELTO product approval overview; selected extract supplied by the parent reviewer

    Parent-supplied selected official overview extract; the parent reviewer inspected the page on 17 November 2026. The delegate did not access the page, and the full page, review documents and label were not appraised. United States approval only; no German or European claim.

  3. 3
    FDA ENCELTO package insert, selected printed pages 10–15, supplied by the parent reviewer

    Selected printed pages 10 to 15 supplied by the parent reviewer from the official package insert on 17 November 2026. Full instruction for use, operative details, figures and remaining pages were not appraised; no full label read is claimed.

  4. 4
    GeneReviews NF1: selected surveillance table6a/6b

    Parent inspected selected surveillance table6a/6b on17November2026; brain MRI clinically indicated, not all-body/current full-guideline appraisal.

  5. 5
    Shields et al2001: clinical variations in150 Coats cases; PMID11336930

    Selected indexed primary results inspected17November2026, not complete main text/figures or full abstract.

Original lecture link